Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tabar, L
Right arrow Articles by Krusemo, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabar, L
Right arrow Articles by Krusemo, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology, Vol 29, Issue 12 608-616, Copyright © 1999 by Foundation for Promotion of Cancer Research

CASE REPORTS

Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening

L Tabar, HH Chen, SW Duffy and UB Krusemo
Mammography Department, Central Hospital, Falun, Sweden.

BACKGROUND: As mammographic screening becomes more widespread, larger numbers of tumours are diagnosed while small and node negative. METHODS: We examined detection mode, tumour size, node status, histological type, therapy and outcome in 1053 breast cancers diagnosed in one county of the Swedish Two-County Trial of mammographic screening for breast cancer. RESULTS: Of patients undergoing total mastectomy with axillary dissection, 65% were found to be node negative. For tumours of size 1-9 mm, 95% were node negative. The major effects on survival were tumour size, node status and histological type. Primary adjuvant therapy had no significant association with survival. CONCLUSIONS: The advent of mammography has substantially enhanced the possibilities for less radical treatment. There is an urgent need for therapeutic trials utilizing mammographic-pathological correlations to ascertain in advance which tumours can and which cannot benefit from more radical therapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
K. Armstrong, E. Moye, S. Williams, J. A. Berlin, and E. E. Reynolds
Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians
Ann Intern Med, April 3, 2007; 146(7): 516 - 526.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
A. B Miller
Commentary: A defence of the Health Insurance Plan (HIP) study and the Canadian National Breast Screening Study (CNBSS)
Int. J. Epidemiol., February 1, 2004; 33(1): 64 - 65.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.